

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hu et al.

Application Serial No.: 09/257,272

Group Art Unit: 1643

Filed: February 25, 1999


Examiner: Not assigned

For: Vascular Endothelial Growth Factor 2

Atty. Docket No.: PF112P2D2

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner For Patents
Washington, D.C. 20231



Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-EI listed on the attached Form PTO-1449. A copy of references AF, BC, and CJ-CN is enclosed.

Applicants request that the references listed on the enclosed Form PTO-1449 be made of record in the present application. Copies of references AA-AE, AG-BB, BD-CI, and CO-EI were previously submitted by Applicants or provided by the Examiner in related U.S. Patent Application Serial No. 09/042,105, filed March 13, 1998, U.S. Patent Application Serial No. 08/999,811, filed December 24, 1997, related U.S. Patent Application Serial No. 08/824,996, filed March 27, 1997, and related U.S. Patent Application Serial No. 08/207,550, filed March 8, 1994. The Examiner is directed to the files of the above-listed applications for copies of references AA-AE, AG-BB, BD-CI, and CO-EI.

Some references cited in the present supplemental IDS were recently brought to the attention of the Applicants in connection with an opposition to an Australian application, that essentially corresponds to the U.S. priority application, U.S. Patent No. 5,935,820.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The Assistant Commissioner is authorized to charge our Deposit Account No. 08-3425 for any fee which may be required in connection with this submission.

Respectfully submitted,

Dated: 2/8/00


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 510-9772

MMW/lcc
Enclosures

